Kanabo Group PLC Expansion:14 New Clinics Partnership with Treat-It

RNS Number : 9281Q

Kanabo Group PLC

04 June 2024

 

Kanabo Group Announces Expansion with 14 New Clinics in Partnership with Treat-It

London, UK - June 4, 2024 - Kanabo Group, a leading health tech company, is pleased to announce a significant expansion of its associated, in-pharmacy clinics to complement its existing online consultants. Using Treat-It, Kanabo's online pain and mental health clinic, offering medicinal cannabis treatments, Kanabo is launching an additional 14 in-pharmacy clinics across the UK.

In addition to the in-pharmacy clinics, the company opened on the 4^th of June a physical clinic in partnership with 360 Med Medical Centre in Muswell Hill, London. This expansion will provide greater access to medical cannabis treatments, and adds additional reach for patients who need or want to have an in-person consultation. The 360 Med Medical Centre offers today a broad range of services, including primary care, mental health, women's health, men's health, pain management and health screening tests.

In addition to these new in-pharmacy clinics, Kanabo is also happy to announce the signing of over 150 referral pharmacies. These pharmacies will be able to refer patients to the online clinic 'Treat It' in a seamless online way, further expanding the reach and accessibility of Kanabo's services.

Avihu Tamir, CEO of Kanabo Group, commented:

"We are demonstrating relentless progress based on our expansion plan set in our previous financial reports in achieving the target of 10 new clinics by the end of Q3, as set in the last yearly report, This step will expand our reach to patients both online and in-person consultations, providing safe access to medical cannabis for those patients who will benefit from these treatments".

New In Pharmacy Clinic Locations:

●    360 Med Medical Centre - Muswell Hill, London

●    Styvechale Pharmacy - Coventry

●    Newington Pharmacy - Edinburgh

●    Village Pharmacy - Bramhall, Stockport

●    Pinxton Pharmacy - Pinxton

●    Werrington Pharmacy - Werrington

●    Beechdale Pharmacy - Nottingham

●    Fenton Pharmacy - Stoke-on-Trent

●    Amber Pharmacy - Ilkeston

●    Eccleshall Pharmacy - Stafford

●    Adswood Pharmacy - Stockport

●    Fir Road Pharmacy - Stockport

●    Dial House Pharmacy - Stockport

●    Singers Chemist - Cheadle

Enquiries:

 

Kanabo Group plc Avihu Tamir, Chief Executive Officer Assaf Vardimon, Chief Financial Officer Ian Mattioli, Non-Executive Chair of the Board	[phone]
Peterhouse Capital Limited (Financial Adviser and Broker) Eran Zucker / Lucy Williams / Charles Goodfellow	[phone]

 

About Kanabo Group plc

Kanabo Group plc (LSE:KNB) is a digital health company committed to transforming patient care through its innovative technology platform and specialised treatment offerings. Since its inception in 2017, Kanabo has been focused on researching, developing, and commercialising regulated medicinal cannabis-derived formulations and therapeutic inhalation devices.

 

Kanabo's NHS-approved online telehealth platform, The GP Service, provides patients with video consultations, online prescriptions, and primary care services. Leveraging its telehealth capabilities, in February 2023, Kanabo launched Treat It, an online clinic focused on chronic pain management that provides patients with secondary care.

 

With its two complementary business divisions, Kanabo has established itself as an end-to-end digital health provider. It offers telehealth consultations, prescriptions and tailor-made treatments.

 

The Company's partially owned subsidiary, Kanabo Agritec Ltd, is a cultivation consultancy supporting cannabis businesses in developing new farms through infrastructural, research, and product guidance. These farms deliver high-quality raw materials for Kanabo's formulas and product line.

 

At Kanabo Group Plc, we are dedicated to providing patients with the highest quality medical treatments and more accessible healthcare experiences.

Visit www.kanabogroup.com for more information.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

UPDBUGDLSUGDGSX